Categories
All News Coronavirus COVID-19 Market Impact Industry Analytics Market Reports

Asia Pacific IVD Market 2026 Industry Analysis, Advance Prospects, Worldwide Demand By Top Companies

Asia Pacific In-vitro diagnostics market is expected to register a CAGR of 5.6% during 2016 to 2022. The reagent segment is expected to maintain dominance, accounting for around 60% of the overall Asia-Pacific IVD market.

In vitro diagnostics is a technique used to identify several diseases and health conditions in a controlled artificial environment. The wide scope of application in various biological and medical diagnostics industries offers a competitive edge to the IVD device and reagents manufacturers. Likewise, factors such as, increasing government initiatives, growing R&D activities for advanced diagnostics techniques, improving healthcare infrastructure, and rising per capita healthcare expenditure largely drive the Asia Pacific IVD market growth. On the other hand, lack of harmonization in regulatory guidelines coupled with inadequate reimbursement policies and technological barriers are hindering the market growth.

Download free sample Report @ https://www.alliedmarketresearch.com/request-sample/1256

The Asia-Pacific IVD market is categorized into several diagnostic techniques, among which, the immunodiagnostic and clinical chemistry segments hold the dominant share collectively accounting for half of the market share in 2015. The growing trend of diagnostic tools such as, clinical chemistry and molecular diagnostic would largely drive the market growth during the forecast period. However, blood testing is projected to be the fastest growing segment, owing to its frequent application and inherent convenience of using blood samples.

In 2015, the immune system disorder and infectious diseases application segments together held a dominant share, of around 50% of the Asia-Pacific IVD market. This is attributed to the growing incidence and prevalence of infectious diseases namely, HIV/AIDS and Hepatitis; and immune systems disorders namely, diabetes, and immune deficiency. The Stand-alone laboratories and hospital end user segments dominated the market in 2015 owing to frequent and primary use of in vitro diagnostic techniques for the detection of several diseases and disorders.

Key findings of the study:

  • Infectious diseases segment is expected to maintain its foothold in the Asia-Pacific IVD market.
  • Cancer is projected to be the fastest growing application segment during the forecast period.
  • In 2015, infectious diseases and immune system disorders collectively accounted for about half of the Asia-Pacific IVD indication market.
  • Asia-Pacific IVD Instruments market is projected to witness the highest CAGR of 7.1% during the forecast period.
  • India is forecasted to be the fastest growing market, growing at a CAGR of 7.1% from 2016 to 2022.
  • In 2015, China and Japan collectively accounted for around two-third of the Asia Pacific IVD market revenue.

Discount on Purchase @ https://www.alliedmarketresearch.com/purchase-enquiry/1256

In 2015, China and Japan, collectively accounted for about two-third of the Asia-Pacific IVD market and the growth is largely supplemented by heavy R&D investments by companies and the increased adoption of innovative IVD techniques. Australia and India would emerge as lucrative markets, owing to the growing awareness related to the chronic diseases and increasing disposable income of these economies

The leading companies profiled in this report are, F. Hoffmann-La Roche AGR, Abbott Laboratories, Danaher Corporation, Johnson & Johnson, Sysmex Corporation, Becton Dickinson and Company, bioMrieux, Thermo Fisher Scientific, Inc., Ortho-Clinical Diagnostics, Siemens AG, and Alere Inc, Vela Diagnostics, Affymetrix, Alere Inc., Bio-Rad Laboratories, Arkray Inc., Sysmex Corporation, and Trans Asia BioMedicals Ltd.

Categories
All News Coronavirus COVID-19 Market Impact Market Reports

In Vitro Diagnostics (IVD) Quality Control Product Market Huge Growth Opportunities | Industry Trends | Market Analysis & Global Forecast to 2026

The global IVD quality control products market was valued at $823 million in 2015, and is expected to reach $1,052 million by 2022, registering a CAGR of 3.5% from 2016 to 2022. The quality controls products segment dominated the market with fourth-fifths share in 2015. Immunochemistry and clinical chemistry application segments together captured around half of the market share in 2015.

The IVD quality control products market is driven by factors such as increasing number of accredited laboratories, stringent mandates on the use of third party IVD quality control products, and increase in the number of IVD test volumes across the globe. Increase in adoption of multianalyte controls and focus of key players on expanding their market presence in emerging economies are anticipated to create new growth opportunities for market players. However, poor reimbursement scenario and lack of regulations regarding the use of controls in emerging economies are expected to hamper the market growth during the analysis period.

Download free sample Report @ https://www.alliedmarketresearch.com/request-sample/1792

The growth of the global IVD quality control products market is propelled by increase in adoption of multianalyte third party quality controls, says Hemali Narkhede, Manager, and Healthcare Research at Allied Market Research. She further added, serum/plasma-based controls products are popular due to their high stability and long self life.

In 2015, the quality controls segment accounted for the largest market share in the global market due to the upsurge in demand for third-party quality controls. The serum/plasma based controls accounted for the largest share in the quality controls market in 2015, and is estimated to grow at the fastest CAGR of 4.1% from 2016 to 2022, owing to the increase in demand for products with long self-life and high stability. The immunochemistry application segment dominated the global market by application in 2015, owing to the rise in demand for high-sensitivity immunochemistry tests and increase in availability of multianalyte controls to test the accuracy of large immunoassay test menus.

Key findings of the study

  • In 2015, quality controls segment dominated the IVD quality control products market. It is projected to grow at a CAGR of 3.7% during the forecast period.
  • North America contributed the largest share in the global IVD quality control products market in 2015, and is projected to grow at a CAGR of 3.3% from 2016 to 2022.
  • The immunochemistry application segment holds the largest share in the global IVD quality control products market, and is projected to grow at a CAGR of 4.2% during the forecast period.
  • The U.S. was the major shareholder in the North American market in 2015.
  • The Japan was the major shareholder in the Asia-Pacific market in 2015 with around half of market share.

Discount on Purchase @ https://www.alliedmarketresearch.com/purchase-enquiry/1792

North America was the highest revenue contributor to the global market. Asia-Pacific is projected to be the fastest-growing region by 2022, registering a CAGR of 4.9% during the forecast period, due to increase in acceptance of third party IVD control products and spiraling number of accredited laboratories in the region.

The key players in the IVD quality control products market have focused on expanding their business operations in the emerging economies by adopting strategies such as new product launches and geographical expansion. The major market players profiled in the report include Abbott Diagnostics, Bio-Rad Laboratories, Inc., Roche Diagnostics, Thermo Fisher Scientific, Inc., Randox Laboratories Ltd., Helena Laboratories, Seracare Life Sciences, Inc., Technopath Clinical Diagnostics, and Sun Diagnostics, LLC.

Related News:

https://www.scribd.com/document/469143609/Pain-Management-Device-Market-Size-Industry-Forecast-by-2026

https://www.scribd.com/document/469144190/MS-Therapies-Market-Size-and-Share-Industry-Growth-2026